05.16.13
MPI Research has created a new division, Surgical Services and Medical Device Evaluation (SMD), which will be led by senior director, Mark Johnson. Mr. Johnson has more than 15 years of GLP and non-GLP experience in this field. He leads a team of surgeons and study directors that have extensive experience in medical device evaluation and surgical model development.
The division incorporates three areas: targeted delivery of therapeutics, medical device evaluation, and surgically induced disease models. The division also provides surgical support services to all of MPI Research. The surgical facilities at MPI Research consist of three large animal suites and one small animal suite.
MPI Research chairman, president, and chief executive officer, William U. Parfet, MBA, said, “Our new division has been driven by sponsor demand. Medical device, pharmaceutical, and biotech companies know that by placing their studies with us, they will get the best possible surgery and medical device evaluation in the preclinical space. They appreciate that not only have we dedicated an entire division to meet their needs, but we can also address their other preclinical and early clinical research requirements all within the same facility. This brings continuity and cost-effectiveness to their drug and device programs, while minimizing the risk of inconsistency and error since they can get all their research needs met by a single CRO.”
The division incorporates three areas: targeted delivery of therapeutics, medical device evaluation, and surgically induced disease models. The division also provides surgical support services to all of MPI Research. The surgical facilities at MPI Research consist of three large animal suites and one small animal suite.
MPI Research chairman, president, and chief executive officer, William U. Parfet, MBA, said, “Our new division has been driven by sponsor demand. Medical device, pharmaceutical, and biotech companies know that by placing their studies with us, they will get the best possible surgery and medical device evaluation in the preclinical space. They appreciate that not only have we dedicated an entire division to meet their needs, but we can also address their other preclinical and early clinical research requirements all within the same facility. This brings continuity and cost-effectiveness to their drug and device programs, while minimizing the risk of inconsistency and error since they can get all their research needs met by a single CRO.”